Clinical Trial: Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07809906) titled 'Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression' on Aug. 27.

Brief Summary: The goal of this Phase 1 clinical trial is to understand whether a new experimental treatment, called ORM-1153, will be a safe and possibly effective treatment option for participants with blood cancers such as Acute Myeloid Leukemia (AML) which have a particular protein (called Cluster of Differentiation 123 or CD123) on the cancer cell's surface. Phase 1 studies are designed to find a safe and effective dose.

Participants will be receiving ORM-1153 at the defined study frequency as an infusion into the vein. They will need to visi...